Matching articles for "vinorelbine"
Issue 1723 · March 3, 2025
Datopotamab Deruxtecan (Datroway) for Advanced Breast Cancer (online only)

The FDA has approved datopotamab deruxtecan ( Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of…

Med Lett Drugs Ther. 2025 Mar 3; 67(1723):e41-2 doi:10.58347/tml.2025.1723e
The FDA has approved datopotamab deruxtecan ( Datroway – Daiichi Sankyo/AstraZeneca), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer who received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
Issue 1705 · June 24, 2024
Tisotumab Vedotin (Tivdak) for Cervical Cancer (online only)

Tisotumab vedotin-tftv ( Tivdak – Seagen/Genmab), a tissue factor-directed antibody and microtubule inhibitor conjugate, has received full approval from the FDA for treatment of recurrent or metastatic…

Med Lett Drugs Ther. 2024 Jun 24; 66(1705):e109-10 doi:10.58347/tml.2024.1705g
Tisotumab vedotin-tftv ( Tivdak – Seagen/Genmab), a tissue factor-directed antibody and microtubule inhibitor conjugate, has received full approval from the FDA for treatment of recurrent or metastatic cervical cancer that progressed on or after chemotherapy. It is the first antibody-drug conjugate to be approved for treatment of cervical cancer. The drug received accelerated approval from the FDA in 2021 for the same indication.
Issue 1671 · March 6, 2023 Free
In Brief: A New Breast Cancer Indication for Sacituzumab Govitecan (Trodelvy) (online only)

Sacituzumab govitecan-hziy ( Trodelvy – Gilead) has been approved for treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2023 Mar 6; 65(1671):e43-4 doi:10.58347/tml.2023.1671g
Sacituzumab govitecan-hziy ( Trodelvy – Gilead) has been approved for treatment of unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in adults who received prior endocrine therapy and ≥2 additional systemic therapies for metastatic disease. It was previously approved for treatment-refractory metastatic triplenegative breast cancer and for treatment of locally advanced or metastatic urothelial cancer in adults who received platinum-based chemotherapy and a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Issue 1664 · November 28, 2022
Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)

The FDA has approved margetuximab-cmkb ( Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy for treatment of metastatic human epidermal growth factor receptor 2…

Med Lett Drugs Ther. 2022 Nov 28; 64(1664):e195-6
The FDA has approved margetuximab-cmkb ( Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy for treatment of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adults who received ≥2 prior anti-HER2 regimens, at least one of which was for metastatic disease.
Issue 1617 · February 8, 2021
Sacituzumab Govitecan (Trodelvy) for Metastatic Triple-Negative Breast Cancer (online only)

The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with…

Med Lett Drugs Ther. 2021 Feb 8; 63(1617):e24-5
The FDA has approved sacituzumab govitecan-hziy ( Trodelvy – Immunomedics), a trophoblast cell-surface antigen-2 (Trop-2)-directed antibody and topoisomerase inhibitor conjugate, for treatment of adults with metastatic triple-negative breast cancer who have received ≥2 prior therapies for metastatic disease. It is the first Trop-2-directed antibody-drug conjugate to become available in the US.
Issue 1362 · April 18, 2011
Eribulin Mesylate (Halaven) for Breast Cancer

Eribulin mesylate ( Halaven – Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer.…

Med Lett Drugs Ther. 2011 Apr 18; 53(1362):30-1
Eribulin mesylate ( Halaven – Eisai) has been approved by the FDA for treatment of patients with metastatic breast cancer who have previously received at least 2 chemotherapy regimens for metastatic cancer. Prior therapy should have included an anthracycline and a taxane in either an adjuvant or metastatic setting. Other drugs used to treat anthracycline- and taxane-refractory metastatic breast cancer include capecitabine (Xeloda) , gemcitabine ( Gemzar , and others) and vinorelbine ( Navelbine , and others).
Issue 7 · March 1, 2003
Drugs of Choice for Cancer

The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…

Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.
Issue 1087 · September 18, 2000
Drugs of Choice For Cancer Chemotherapy (combined issue 1087-1088)

The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for…

Med Lett Drugs Ther. 2000 Sep 18; 42(1087):83-92
The tables in this article list drugs used for treatment of cancer in the USA and Canada. The choices of drugs in Table 1 is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. For many of the cancers listed, surgery and/or radiation therapy are also part of the management of the disease.
Issue 955 · August 18, 1995
Vinorelbine For Treatment of Advanced Non-Small-Cell Lung Cancer

Vinorelbine ( Navelbine - Burroughs Wellcome), a semisynthetic vinca alkaloid, has been approved by the US Food and Drug Administration for parenteral use in the treatment of advanced non-small-cell lung…

Med Lett Drugs Ther. 1995 Aug 18; 37(955):72-3
Vinorelbine ( Navelbine - Burroughs Wellcome), a semisynthetic vinca alkaloid, has been approved by the US Food and Drug Administration for parenteral use in the treatment of advanced non-small-cell lung cancer (NSCLC). Various combinations of cisplatin ( Platinol ), vinblastine ( Velban , and others), mitomycin ( Mutamycin ), ifosfamide ( Ifex ), etoposide ( VePesid ) and paclitaxel ( Taxo l) have been used previously for this indication.